evinacumab   Click here for help

GtoPdb Ligand ID: 8717

Synonyms: evinacumab-dgnb | Evkeeza® | REGN1500
Approved drug
evinacumab is an approved drug (EMA & FDA (2021))
Compound class: Antibody
Comment: Evinacumab is a fully human monoclonal antibody targeting angiopoietin-like 3 (ANGPTL3). Due to its role in lipid metabolism, ANGPTL3 is being investigated as a potential molecular target for the treatment of hypertriglyceridemia.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.
A BLAST search of patented peptide sequences reveals that the heavy chain variable domain of evinacumab is identical to SEQ ID: NO 66 from patent US9018356 B2 [3], and the light chain variable region is identical to SEQ ID: NO 74 from the same patent (this heavy/light chain combination corresponds to antibody identifier H4H1276S).

Evinacumab utilises a different molecular mechanism compared to Regeneron's already approved anti-hyperlipidemic drug alirocumab (targets proprotein convertase subtilisin/kexin type 9).
Classification Click here for help
Compound class Antibody
Approved drug? Yes (EMA & FDA (2021))
Approved drug? Yes. FDA (2021)  |  EMA (2021)
International Nonproprietary Names Click here for help
INN number INN
10013 evinacumab
Synonyms Click here for help
evinacumab-dgnb | Evkeeza® | REGN1500
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 529
Other databases
GtoPdb PubChem SID 252827375
Search PubMed clinical trials evinacumab
Search PubMed titles evinacumab
Search PubMed titles/abstracts evinacumab